Compare HFWA & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | EVO |
|---|---|---|
| Founded | 1927 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 778.3M |
| IPO Year | 1997 | 2007 |
| Metric | HFWA | EVO |
|---|---|---|
| Price | $28.80 | $1.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $30.50 | $7.00 |
| AVG Volume (30 Days) | ★ 329.3K | 41.3K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 58.06 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.85 | $1.37 |
| Revenue Next Year | $7.83 | $10.05 |
| P/E Ratio | $31.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.32 | $1.87 |
| 52 Week High | $31.25 | $4.27 |
| Indicator | HFWA | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 35.95 |
| Support Level | $28.94 | N/A |
| Resistance Level | $29.29 | $2.20 |
| Average True Range (ATR) | 0.45 | 0.05 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 28.81 | 0.00 |
Heritage Financial Corp is a bank holding company. The company, through its subsidiary, provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as non-interest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.